Category: hypertrophic cardiomyopathy

Cytokinetics stock soars on heart drug data that sets stage for Phase 3 studies

BioPharma, biopharma nl, cardiovascular health, Clinical Trials, Cytokinetics, Daily, FDA, hypertrophic cardiomyopathy, Pharma, Robert Blum, South San Francisco, SYN, Top Story / July 19, 2021 July 19, 2021

A Cytokinetics drug in development for treating a rare heart disorder has promising Phase 2 data suggesting it could compete against a Bristol Myers Squibb drug currently under FDA review. Cytokinetics plans to advance its small molecule to Phase 3 testing by the end of this year.

Look out BMS, Cytokinetics has its eye on mavacamten’s turf

Bristol-Myers Squibb, cardiology, Cytokinetics, hypertrophic cardiomyopathy, mavacamten, MyoKardia, News, R&D / July 19, 2021 July 19, 2021

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb’s mavacamten – acquired as part of its $13.1 billion takeover of MyoKardia last October. In HCM, the heart muscle become thickened and in some patients can obstruct blood …

Look out BMS, Cytokinetics has its eye on mavacamten’s turf Read More »

BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B

BioPharma, biopharma nl, Bristol-Myers Squibb, cardiovascular disease, Daily, danicamtiv, hypertrophic cardiomyopathy, M&A, mavacamten, MyoKardia, New York, SYN, Top Story / October 6, 2020 October 6, 2020

The companies expect the deal to close in the fourth quarter. MyoKardia’s lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.